OnKure Therapeutics, Inc. — fact timeline

OnKure Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

“OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.”

OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).

“the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.”

OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).

“On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).”

Andrew Phillips was appointed as Chair of the Board at OnKure Therapeutics, Inc..

“Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.”

Michael Grey was appointed as Class III Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Andrew Phillips was appointed as Class III Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Edward T. Mathers was appointed as Class II Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Valerie M. Jansen was appointed as Class II Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

R. Michael Carruthers was appointed as Class II Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Isaac Manke was appointed as Class I Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Nicholas Saccomano was appointed as Class I Director at OnKure Therapeutics, Inc..

“Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.”

Ashley F. Hall was terminated as Chief Development Officer at OnKure Therapeutics, Inc..

“the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.”

OnKure Therapeutics, Inc. entered into Merger Agreement with Reneo Pharmaceuticals, Inc. (effective 2024-05-10).

“On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“ Reneo ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (“ Merger Sub I ”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (“ Merger Sub II ”), and OnKure, Inc., a Delaware corporation (“ OnKure ”)”

Ashley F. Hall departed as other_named_officer at OnKure Therapeutics, Inc..

“each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.”

Alejandro Dorenbaum departed as other_named_officer at OnKure Therapeutics, Inc..

“each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.”

Gregory J. Flesher departed as other_named_officer at OnKure Therapeutics, Inc..

“each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.”

OnKure Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $8.4 million, or $0.25 per share, EPS $0.25 per share.

“We reported a net loss of $8.4 million, or $0.25 per share, during the first quarter of 2024, compared to a net loss of $15.1 million, or $0.60 per share, for the same period in 2023.”